Christina Farr

The biggest winners from the Hinge IPO - and what that says about digital health investing

One tiny fund I hadn’t heard of absolutely crushed it

Why tech and medicine need each other with GC's Steve Klasko & THL Partners' Jessie Beegle

In this episode of Second Opinion, Christina Farr, Stephen Klasko and Jessica Beegle, discuss the persistent challenges in healthcare despite

Should you build relationships with VCs before a raise? That’s a hard yes.

This is a hot topic and I’ve heard plenty of arguments with both sides. Here’s my POV.

Healthcare’s “original sin” with Stephen Buck, CEO of Courage Health

This week on Second Opinion, Christina Farr and Ash Zenooz interview Stephen Buck, CEO/Co-Founder of Courage Health.

Second Opinion x Steve Buck

Speaking from experience: arguments for & against building a homegrown EHR

More perspectives from experienced operators on the great build vs. buy question for fundamental technology used by digital health cos

A deeper dive on Hinge vs Omada

Lets compare the s-1s of two interesting digital health companies are going public in 2025

The power of patient data & the future of health tech with Microsoft's Peter Lee and Dave deBronkart

This week on Second Opinion, we're sharing an episode from Peter Lee's Microsoft Research Podcast with guests Dave deBronkart and Christina Farr.

Why employers are recruiting strong public health communicators

Employers tell me that preventative health is harder than ever

OMG! Omada Health just filed its S1.

Omada got its start in 2011.

How dietary guidelines changed our rate of aging with Stephanie Venn-Watson

This week on Second Opinion, Christina Farr and Ash Zenooz interview Seraphina Therapeutics CEO Steph Venn-Watson, unpacking why men dominate the longevity space, the cellular secrets of aging, and C15:0’s potential to boost health.

Some tough questions VCs and founders need to address out in the open

What are the hidden trade offs of fund size. When should founders be able to take money off the table?